M.G. Peters , H.W. Hann, P. Martin, E. Jenny Heathcote, P. Buggisch, R. Rubin, M. Bourliere, K. Kowdley, C. Trepo, D.F. Gray, M. Sullivan, K. Kleber, R. EbrahimiS. Xiong, C. L. Brosgart, for the GS 00 461 study group. Adefovir Dipivoxil Alone or in Combination with Lamivudine in Patients with Lamivudine-Resistant Hepatitis B Virus Gastroenterology 2004: 26:91-101
Raymond T. Chung, M.D., Janet Andersen, Paul Volberding, Gregory K. Robbins, Tun Liu, Kenneth E. Sherman, M.G. Peters , Margaret J. Koziel, Beverly Alston, Dodi Colquhoun, Tom Nevin, George Harb and Charles van der Horst, for the A5071 Study Team. A randomized, controlled trial of PEG interferon alfa 2a plus ribavirin versus interferon alfa 2a plus ribavirin for chronic Hepatitis C virus infection in HIV co-infected persons: the US AIDS Clinical trials Group A5071 study team. N Engl J Med. 2004 Jul 29;351(5):451-9
Kenneth E. Sherman, Paul Horn, Norah Shire, Susan Rouster, M.G. Peters , Margaret Koziel, Raymond T. Chung, and the ACTG 5071/5091s Study Group. Viral Kinetic Modeling in HCV/HIV Coinfected Patients Treated with Pegylated Interferon and Ribavirin. Gatroenterology In press 2004.
C. Graham, A. Wells, T. Liu, K. E. Sherman, M.G. Peters , R. Chung, J. Andersen, and M. Koziel for the ACTG 5071 Study Team. Relationships between Hepatitis C Virus-Specific Immune Responses and Outcome of Treatment with Interferon and Ribavirin in HIV/HCV Coinfection submitted.
M.G. Peters , Janet Andersen, Ray Chung, Margaret Koziel, Kenneth Sherman, and Ray Apple for the ACTG A5071 Protocol Team. DNA Polymorphisms in Inflammatory Mediators Affect Severity of Disease and Response to Therapy in Subjects Co-infected with HCV and HIV: ACTG A5071. In preparation. |
